Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00011362 · ClinicalTrials.gov registry record · Phase 3

Dexamethasone Therapy in VLBW Infants at Risk of CLD

A Phase 3 study, sponsored by NICHD Neonatal Research Network.

Completed
Registry status
Phase 3
Development phase
371
Enrollment target

NCT00011362 is a Phase 3 study that has completed, run by NICHD Neonatal Research Network. The registered enrollment target is 371 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00011362, a Phase 3 study, has completed, sponsored by NICHD Neonatal Research Network.

COMPLETED
Registry status
Phase 3
Development phase
371 participants
Enrollment target

Study Summary

Infants who are on breathing support are often treated with steroids (dexamethasone); however, the best timing of therapy is not known. This trial looked at the benefits and hazards of starting dexamethasone therapy at two weeks of age and four weeks of age in premature infants.

Interventions

  • DRUG Dexamethasone Early
  • DRUG Dexamethasone Late

Trial Details

FieldValue
Enrollment Target 371 participants
Start Date 1992-09
Est. Completion 1994-04
Phase Phase 3

Sponsor

NICHD Neonatal Research Network

61 total trials

What the Registry Record Tells You About NCT00011362

The ClinicalTrials.gov registry entry for NCT00011362 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 371 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NICHD Neonatal Research Network, which has 61 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Dexamethasone Early is the first listed.

NCT00011362 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00011362 about?

NCT00011362 is a clinical study titled "Dexamethasone Therapy in VLBW Infants at Risk of CLD". Infants who are on breathing support are often treated with steroids (dexamethasone); however, the best timing of therapy is not known. This trial looked at the benefits and hazards of starting dexamethasone therapy at two weeks of age and four weeks of age in premature infants.

What is the current status of trial NCT00011362?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 371 participants. The study started on 1992-09. Estimated completion is 1994-04.

What interventions are being tested in trial NCT00011362?

The interventions under investigation include: Dexamethasone Early (DRUG), Dexamethasone Late (DRUG).

Who is sponsoring clinical trial NCT00011362?

This trial is sponsored by NICHD Neonatal Research Network, which has 61 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.